ATE339414T1 - Chinazolinverbindungen mit therapeutischem nutzen - Google Patents

Chinazolinverbindungen mit therapeutischem nutzen

Info

Publication number
ATE339414T1
ATE339414T1 AT03743965T AT03743965T ATE339414T1 AT E339414 T1 ATE339414 T1 AT E339414T1 AT 03743965 T AT03743965 T AT 03743965T AT 03743965 T AT03743965 T AT 03743965T AT E339414 T1 ATE339414 T1 AT E339414T1
Authority
AT
Austria
Prior art keywords
therapeutic benefit
quinazoline compounds
quinazoline
compounds
therapeutic
Prior art date
Application number
AT03743965T
Other languages
English (en)
Inventor
Julian Blagg
Michael J Fray
Mark L Lewis
John P Mathias
Mark H Stefaniak
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE339414T1 publication Critical patent/ATE339414T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
AT03743965T 2002-03-14 2003-03-05 Chinazolinverbindungen mit therapeutischem nutzen ATE339414T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0206033.3A GB0206033D0 (en) 2002-03-14 2002-03-14 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
ATE339414T1 true ATE339414T1 (de) 2006-10-15

Family

ID=9932974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743965T ATE339414T1 (de) 2002-03-14 2003-03-05 Chinazolinverbindungen mit therapeutischem nutzen

Country Status (19)

Country Link
US (1) US6936619B2 (de)
EP (1) EP1483257B1 (de)
JP (1) JP2005532275A (de)
AR (1) AR038949A1 (de)
AT (1) ATE339414T1 (de)
AU (1) AU2003209594A1 (de)
BR (1) BR0308407A (de)
CA (1) CA2479016A1 (de)
DE (1) DE60308332T2 (de)
ES (1) ES2271618T3 (de)
GB (1) GB0206033D0 (de)
GT (1) GT200300059A (de)
HN (1) HN2003000100A (de)
MX (1) MXPA04008939A (de)
PA (1) PA8569501A1 (de)
PE (1) PE20040265A1 (de)
TW (1) TW200305420A (de)
UY (1) UY27711A1 (de)
WO (1) WO2003076427A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ATE335744T1 (de) 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
US20040132728A1 (en) * 2002-09-17 2004-07-08 Pfizer Inc Combinations of atorvastatin and alpha1adrenergic receptor antagonists
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
WO2005005397A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
EP1595881A1 (de) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
ES2552804T3 (es) 2005-05-04 2015-12-02 Evotec Ag Compuestos heterocíclicos condensados, y sus composiciones y usos
EP1790646A1 (de) * 2005-11-24 2007-05-30 Sanofi-Aventis Isoquinolin- und Benzo[h]isoquinolinderivate, deren Herstellung und deren therapeutischen Verwendung als Antagonisten des Histamin-H3-Rezeptors .
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CA2682162C (en) 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
WO2008130481A1 (en) 2007-04-17 2008-10-30 Renovis, Inc. 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
CN101686989B (zh) 2007-06-21 2016-10-19 卡拉治疗学股份有限公司 取代的咪唑并杂环
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2216023A4 (de) * 2007-11-15 2013-03-13 Takeda Pharmaceutical Kondensiertes pyridinderivat und seine verwendung
DK2323997T3 (en) 2008-07-31 2017-12-11 Senomyx Inc METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF SWEET TASTE AMPLIFIERS
MX2021012876A (es) 2009-03-18 2022-06-23 Resverlogix Corp Nuevos agentes anti-inflamatorios.
ES2821018T3 (es) 2009-04-22 2021-04-23 Resverlogix Corp Nuevos agentes antiinflamatorios
WO2011022213A1 (en) * 2009-08-17 2011-02-24 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine pde10 inhibitors
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PE20150626A1 (es) 2012-08-06 2015-05-29 Senomyx Inc Modificador del sabor dulce
MX338885B (es) * 2012-10-15 2016-05-04 Resverlogix Corp Compuestos utiles en la sintesis de compuestos de benzamida.
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
CA2934144A1 (en) * 2013-12-20 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Fused imidazolyl derivatives, their preparation and use as medicaments
SI3149002T1 (en) * 2014-05-28 2018-08-31 F.Hoffmann-La Roche Ag 5-Oxa-2-azabicyclo (2.2.2) octan-4-yl and 5-oxa-2-azabicyclo (2.2.1) heptan-4-yl derivatives as TAAR1 receptor modulators
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN105153048B (zh) * 2015-07-31 2017-10-24 苏州大学 一种2,4‑喹唑啉二酮类化合物的制备方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法
KR20180094939A (ko) 2015-12-17 2018-08-24 메르크 파텐트 게엠베하 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
WO2017131149A1 (ja) * 2016-01-29 2017-08-03 小野薬品工業株式会社 テトラヒドロナフタレン誘導体
SG11201900947RA (en) * 2016-08-08 2019-02-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
EP3814344A1 (de) 2018-08-07 2021-05-05 Firmenich Incorporated 5-substituierte 4-amino-1h-benzo[c][1,2,6]thiadiazin-2,2-dioxide und formulierungen und verwendung davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085213A (en) * 1976-01-28 1978-04-18 Pfizer Inc. Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
JP4031363B2 (ja) * 2001-01-02 2008-01-09 エフ．ホフマン−ラ ロシュ アーゲー α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体

Also Published As

Publication number Publication date
US6936619B2 (en) 2005-08-30
DE60308332D1 (de) 2006-10-26
UY27711A1 (es) 2003-10-31
US20040029859A1 (en) 2004-02-12
HN2003000100A (es) 2003-12-15
EP1483257A1 (de) 2004-12-08
WO2003076427A8 (en) 2004-10-07
GB0206033D0 (en) 2002-04-24
WO2003076427A1 (en) 2003-09-18
BR0308407A (pt) 2005-01-11
AR038949A1 (es) 2005-02-02
ES2271618T3 (es) 2007-04-16
GT200300059A (es) 2003-10-15
MXPA04008939A (es) 2004-11-26
CA2479016A1 (en) 2003-09-18
DE60308332T2 (de) 2007-01-11
EP1483257B1 (de) 2006-09-13
AU2003209594A1 (en) 2003-09-22
PA8569501A1 (es) 2003-12-10
JP2005532275A (ja) 2005-10-27
PE20040265A1 (es) 2004-05-01
TW200305420A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
ATE339414T1 (de) Chinazolinverbindungen mit therapeutischem nutzen
NO20052914D0 (no) Terapeutiske forbindelser
IS7362A (is) Kínasólín efnasambönd
DK1847539T3 (da) Quinazolin-derivater
NO20033203L (no) Terapeutiske heterocykliske forbindelser
IS7471A (is) Ný efnasambönd
IS7879A (is) Ný efnasambönd
ATE368042T1 (de) Cephemverbindungen
DK1667992T3 (da) Quinazolinderivater
IS7827A (is) Ný efnasambönd
IS7381A (is) Efnasambönd
NO20033204D0 (no) Terapeutiske kromonforbindelser
NO20033205L (no) Terapeutiske kromanforbindelser
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20050689L (no) Terapeutisk anvendelse
DE60301239D1 (de) Verbinder
IS7825A (is) Meðferðarfræðileg meðhöndlun
DE60208885D1 (de) Verbinder
NO20045659L (no) Forbindelser
DE60223352D1 (de) Verbinder
DK1597171T3 (da) Terapeutisk mikroskum
DE10301279B8 (de) Verbinder
DE60218623D1 (de) Verbinder
DE60311724D1 (de) Verbinder
SE0100009D0 (sv) Therapeutic compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties